Featured
-
-
Article
| Open AccessAntibodies toward Na+,HCO3–-cotransporter NBCn1/SLC4A7 block net acid extrusion and cause pH-dependent growth inhibition and apoptosis in breast cancer
- Trine V. Axelsen
- , Claus Olesen
- & Ebbe Boedtkjer
-
Article |
An antibody–drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer
- Joan Jacob
- , Liezl E. Francisco
- & Kendra S. Carmon
-
Article
| Open AccessThe multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
- Carolyn J. Edwards
- , Angelica Sette
- & Andrew J. Pierce
-
Review Article
| Open AccessThe arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
- Liese Barbier
- , Paul Declerck
- & Isabelle Huys
-
Article
| Open AccessPF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
- Mark D. Pegram
- , Igor Bondarenko
- & Elizabeth Tan-Chiu
-
Clinical Study
| Open AccessA phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
- Tae Won Kim
- , Anneli Elme
- & Eduard Vrdoljak
-
Molecular Diagnostics
| Open AccessBiomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
- Charles S Fuchs
- , Josep Tabernero
- & Jaffer A Ajani
-
Translational Therapeutics
| Open AccessA functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
- Madelon Q Wentink
- , Henk J Broxterman
- & Henk M W Verheul
-
Translational Therapeutics
| Open AccessFAT1: a potential target for monoclonal antibody therapy in colon cancer
- Piero Pileri
- , Susanna Campagnoli
- & Renata Grifantini
-
Translational Therapeutics
| Open AccessPrognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
- Naoki Takahashi
- , Satoru Iwasa
- & Yasuhide Yamada
-
Mini Review
| Open AccessAntibody-drug conjugates—an emerging class of cancer treatment
- Nikolaos Diamantis
- & Udai Banerji
-
Letter to the Editor
| Open AccessReply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’
- Andrew Rowland
- , Mafalda M Dias
- & Michael J Sorich
-
Letter to the Editor
| Open AccessBRAF-mutated metastatic colorectal cancer between past and future
- Chiara Cremolini
- , Massimo Di Maio
- & Filippo Pietrantonio
-
Mini Review
| Open AccessMicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
- M Pichler
- & G A Calin
-
Epidemiology
| Open AccessHuman papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies
- E M King
- , R Gilson
- & P Sonnenberg
-
Mini Review
| Open AccessStem cells from adipose tissue and breast cancer: hype, risks and hope
- F Bertolini
- , J-Y Petit
- & M G Kolonin
-
Translational Therapeutics
| Open AccessBI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt
- I Pal
- , S Sarkar
- & M Mandal
-
Translational Therapeutics
| Open AccessA novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth
- D Li
- , X Wei
- & J Fang
-
Translational Therapeutics
| Open AccessExogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer
- C-L Soh
- , K McNeil
- & B E Forbes
-
Molecular Diagnostics
| Open AccessPotent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion
- G Jiang
- , C-S Yang
- & Y-Q Liu
-
Translational Therapeutics
| Open AccessManipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells
- Y Zou
- , F Li
- & S H Thorne
-
Molecular Diagnostics
| Open AccessAntitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer
- Q Yang
- , F Zhang
- & C Chen
-
Clinical Study
| Open AccessFirst-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
- D Bianchini
- , A Omlin
- & D C Danila
-
Translational Therapeutics
| Open AccessInterferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway
- C Xie
- , D-Y Xie
- & Z-L Gao
-
Translational Therapeutics
| Open AccessEwing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging
- L Liebsch
- , S Kailayangiri
- & C Rossig
-
Translational Therapeutics
| Open AccessDirecting HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo
- T O Nielsen
- , S Sorensen
- & B S Sorensen
-
Clinical Study
| Open AccessInsulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
- A Naing
- , P LoRusso
- & R Kurzrock
-
Genetics and Genomics
| Open AccessLack of correlation between predicted and actual off-target effects of short-interfering RNAs targeting the human papillomavirus type 16 E7 oncogene
- J E Hanning
- , H K Saini
- & N Coleman
-
Translational Therapeutics
| Open AccessImmune activation by combination human lymphokine-activated killer and dendritic cell therapy
- E J West
- , K J Scott
- & A A Melcher
-
Translational Therapeutics
| Open AccessAttenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF)
- K A Mirza
- , S M Wyke
- & M J Tisdale
-
Clinical Study
| Open AccessEnd-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
- X Castellsagué
- , N Muñoz
- & A Saah
-
Clinical Study
| Open AccessA Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
- J Wang
- , Z Zhao
- & J Wiezorek
-
Translational Therapeutics
| Open AccessTemsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
- Y Wang
- , X-Y Wang
- & H L Kim
-
Editorial
| Open AccessTargeting IGF-1R: throwing out the baby with the bathwater?
- B Basu
- , D Olmos
- & J S de Bono
-
Molecular Diagnostics
| Open AccessTumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
- J B Baker
- , D Dutta
- & S Khambata-Ford
-
Translational Therapeutics
| Open AccessPopulation pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer
- B Royer
- , W Yin
- & X Pivot
Browse broader subjects
Browse narrower subjects
- Antagomir and RNA sponge
- Antibody fragment therapy
- Antibody therapy
- Antisense oligonucleotide therapy
- Cell therapies
- DNA vaccines
- Gene therapy
- Locked nucleic acid
- Meganucleases
- Nucleic-acid therapeutics
- Peptide nucleic acid oligo
- Recombinant peptide therapy
- Recombinant protein therapy
- Recombinant vaccine
- RNA vaccines
- siRNAs
- TAL effector nuclease
- Triplex-forming oligonucleotide
- Zinc finger nuclease